1. Effect of intravenous different drugs on the prevention of restlessness during recovery period of pediatric laparoscopic surgery: a randomized control trial.
- Author
-
Liang ZJ, Liang JM, Nong XL, Chen NQ, Liu AY, Sun XQ, Lu YX, Ou ZX, Li SL, and Lin YN
- Subjects
- Humans, Female, Male, Child, Preschool, Child, Infant, Emergence Delirium prevention & control, Hypnotics and Sedatives administration & dosage, Pneumoperitoneum, Artificial methods, Double-Blind Method, Dexmedetomidine administration & dosage, Laparoscopy methods, Anesthesia Recovery Period, Ketamine administration & dosage
- Abstract
Purpose: To explored the impact of dexmedetomidine and esketamine in mitigating restlessness during the postoperative recovery phase following laparoscopic surgery in children., Methods: 102 individuals aged 1 to 7 years experiencing laparoscopic surgery were randomly allocated into three groups, each accepting 1 μg/kg of dexmedetomidine, 0.3 mg/kg of esketamine, or saline immediately at the end of carbon dioxide pneumoperitoneum. Emergence agitation (EA) occurrence was assessed by PAED scale and 5-point agitation scale. Pain was judged using Face, Legs, Activity, Cry, and Consolability (FLACC) scale. The recovery time, extubation time, and post-anesthesia care unit (PACU) stay time were recorded for all three groups., Results: Patients administered 1 μg/kg of dexmedetomidine (8.8%) and individuals given 0.3 mg/kg of esketamine (11.8%) showed lower incidences of emergence agitation compared to those receiving saline (35.5%; P = 0.009). There was no statistically significant difference in the time to discharge from the PACU among the three groups of patients (P > 0.05). The recovery time and extubation time were notably extended in the dexmedetomidine group (40.88 ± 12.95 min, 42.50 ± 13.38 min) when compared to the saline group (32.56 ± 13.05 min, 33.29 ± 11.30 min; P = 0.009, P = 0.010)., Conclusion: Following CO
2 pneumoperitoneum in pediatric laparoscopic surgeries, the intravenous administration of 1 μg/kg dexmedetomidine or 0.3 mg/kg esketamine effectively lowers EA occurrence without extending PACU time., Competing Interests: Declarations. Conflict of interest: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript., (© 2024. The Author(s).)- Published
- 2025
- Full Text
- View/download PDF